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COST-EFFECTIVENESS OF DIFFERENT PERTUSSIS VACCINATION STRATEGIES FOR THE PROTECTION OF YOUNG INFANTS
Westra TA 1 , Postma MJ 1 , Tamminga HJ 2 , De Vries R 1 1 University of Groningen, Groningen, The Netherlands, 2 GlaxoSmithKline, Zeist, The Netherlands OBJECTIVES: Despite good vaccination coverage rates and good a-cellular pertussis vaccine efficacy the incidence is still relatively high in The Netherlands. Pertussis is most severe in infants too young for already having completed the primary immunization schedule. For protection of young infants (below one year of age) further strategies should be considered. It is known that household members are an important source of transmission for these infants. The objective of this study was to analyze cost-effectiveness of specific vaccination strategies in The Netherlands explicitly targeting pertussis in these young infants. METHODS: Data were extracted from national registries on incidence, hospitalizations and neonatal intensive care. Additionally, literature and expert consultations were used to complete information on morbidity and accompanying direct costs for pertussis in infants. A static decision analysic model was constructed for estimating health outcomes and costs potentially associated with different vaccination strategies. The strategies investigated were cocooning (father and mother), pre-and postpregnancy maternal immunization, all to protect the infant for transmission of pertussis in the household setting. RESULTS: Relatively, the potential most effective strategy would to be cocooning. However this would also be the most expensive. Compared to do-nothing, incremental cost-effectiveness of the three strategies varied from €15,000 to just over €100,000 per hospitalization averted in the base case. Results appeared to be robust in sensitivity analysis. Under plausible assumptions, pre-pregnancy maternal immunization could well be the most cost-effective strategy. We note that the overall impact on total numbers of infections among young infants obviously crucially depends on the vaccination coverage achieved. CONCLUSION: Cost-effectiveness analysis as presented here is crucial in the Dutch decision making concerning additional pertussis vaccination strategies to protect young infants against severe disease. Further research is needed to fully assess the effectiveness of these strategies, inclusive the application of dynamical models for the spread of pertussis. (WHO 2006) and is one of the main causes of chronic hepatic disease. HCV infection progresses to chronic form in 80% of infected individuals. Approximately 20% progress to cirrhosis over 20 years and, consequently, a high risk of developing hepatocellular carcinoma population. Our objective is to assess the incremental cost-effectiveness ratio (ICER) of peginterferon-alfa-2a (40 KD) plus ribavirin (PEG + RBV) versus interferon-alfa-2b plus ribavirin (IFN + RBV) in the treatment of patients with chronic hepatitis C, genotypes 2 and 3 in the Brazilian payer perspective. METHODS: A Markov model was built to estimate the clinical and economic impact related to the incorporation of peginterferon-alfa-2a (40 KD). Clinical stages were based on liver histology, forms of cirrhotic decompensation, liver cancer and liver transplantation. A Delphi panel was performed for evaluating the direct medical resources related to each clinical stage in chronic hepatitis C, as well as costs from treatment with peginterferon-alfa-2a (40 KD), interferon alfa-2b and ribavirin. Effectiveness of treatment with peginterferon-alfa-2a (40 KD) was obtained from a multicenter, controlled, randomized trial involving 1,121 naive patients with chronic hepatitis C (Fried, M. W. et al, 2002) . We have assumed a discount rate of 3.5% for costs and outcomes according to NICE and a lifetime horizon. A sensitivity analysis was conducted using second-order Monte Carlo simulation. Tested parameters were costs per stage, treatment costs, discount rate, response rate to treatment and early patient distribution. RESULTS: The ICER of PEG + RBV versus IFN + RBV was approximately R$18,627 per life year gained (LYG). The 95% confidence interval for the ICER ranged from R$9,571 to R$29,090. CONCLUSION: The study suggests peginterferon-alfa-2a (40 KD) to be a cost-effective therapy for the private health care system in Brazil.
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COST-EFFECTIVENESS OF PEGINTERFERON-ALFA-2A (40 KD) ASSOCIATED WITH RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPES 2 AND 3 IN BRAZIL
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COST-EFFECTIVENESS OF LINEZOLID VS.VANCOMYCIN IN COMPLICATED SKIN AND SOFT-TISSUE INFECTION DUE TO SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN FRANCE
De Cock E 1 , Besnier JM 2 , Dupon M 3 , Guéry B 4 , Levrat F 5 1 United BioSource Corporation, Barcelona, Spain, 2 CHRU Bretonneau, Bretonneau, France, 3 Hôpital Pellegrin, Bordeaux, France, 4 Hôpital Calmette, CHRU Lille, Lille, France, 5 Pfizer, Paris, France OBJECTIVES: Studies have shown similar clinical cure rates and shorter length of stay (LOS) for linezolid compared to vancomycin in patients with complicated skin and soft tissue infections (cSSTI) due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). This study examined the clinical and economic consequences of using linezolid vs. vancomycin from the French health system perspective. METHODS: A decisionanalytic model followed an average patient from initiation of empiric treatment until successful 1st-line treatment, death, or 2nd-line treatment failure. Efficacy data were derived from published clinical trials. Resource utilization patterns were collected through structured interviews with 4 French physicians experienced in treating cSSTI. Costs from official price and tariff lists were applied to antibiotics therapy, hospitalisation (by ward type), isolation, tests, adverse events, and post-discharge. Patients could be discharged to oral linezolid. The base case used therapy duration and LOS from the expert panel. Outcomes included total cost per patient, and cost per cure. RESULTS: Average total cost per episode was €7784 for linezolid vs. €8514 for vancomycin (cost savings of €730 mostly due to reduction in hospitalization costs from earlier discharge). Mean LOS after two lines of treatment was 10.7 days for linezolid vs. 13.3 days for vancomycin. An additional 0.5% of patients treated with linezolid (98.5%) vs. vancomycin (98.0%) were cured. Slight increase in effectiveness and reduced cost made linezolid the dominant treatment strategy. One-way sensitivity analysis on selected parameters (50% variation above or below baseline), and a conservative scenario with simultaneous changes in key parameters, did not change the overall conclusions (linezolid remained cost-saving). CONCLUSION: This model showed that linezolid could be cost saving when treating patients with cSSTI due to suspected MRSA, while overall clinical cure was similar. Linezolid could therefore be considered an efficient strategy for treating cSSTI in France.
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COST-EFFECTIVENESS OF LINEZOLID VS.VANCOMYCIN IN NOSOCOMIAL PNEUMONIA DUE TO SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN FRANCE
De Cock E 1 , Timsit JF 2 , Carlet J 3 , Leroy O 4 , Wolff M 5 , Levrat F 6 1 United BioSource Corporation, Barcelona, Spain, 2 Hôpital Albert Michallon, Grenoble, France, 3 Groupe Hospitalier Paris Saint Joseph, Paris, France, 4 Hôpital Guy Chatiliez, Tourcoing, France, 5 Hôpital Bichat Claude Bernard, Paris, France, 6 Pfizer, Paris, France OBJECTIVES: Linezolid has demonstrated improved survival and clinical cure rates in hospitalised patients with nosocomial pneumonia (NP) caused by known or suspected methicillinresistant Staphylococcus aureus (MRSA). This study assessed the cost-effectiveness of linezolid vs. vancomycin from the perspective of the French health system. METHODS: A decisionanalytic model followed an average patient from initiation of empiric treatment until successful 1st-line treatment, death, or 2nd-line treatment failure. Efficacy data were derived from published clinical trials. Five French physicians experienced in treating NP provided resource utilization data through structured interviews. Costs from official price and tariff lists were applied to antibiotic therapy, hospitalisation (by ward type), isolation, tests, and adverse events. The model applied similar length of successful 1st-line treatment for linezolid and vancomycin. The model base case conservatively assumed that length of stay was equal to therapy duration. Outcomes included total cost per patient, cost per cure, cost per death avoided, and cost per life year gained. RESULTS: An additional 7.6% of patients treated with linezolid (70.9%) vs. vancomycin (63.2%) were cured. Average total cost per episode was €16,732 for linezolid vs. €15,375 for vancomycin, Modelled survival was 80.4% (linezolid) vs. 69.7% (vancomycin), resulting in an average 2.0 life-years gained per linezolid patient in a 65-year-old cohort (14.9 vs. 13.0 years). Costs per life-year gained (excluding future costs) and death avoided were €685 and €12,727, respectively. One-way sensitivity analysis on selected parameters (50% variation above or below baseline) did not change the overall conclusions. CONCLUSION: Improved clinical outcomes, but increased cost per episode were calculated for linezolid-treated patients. The results suggest that linezolid can be considered a cost-effective alternative for treating patients with NP due to suspected MRSA in France. (NP) . In patients with MRSA-NP, survival and clinical cure rate was higher for patients treated with linezolid (80% and 59%, respectively) than those treated with vancomycin (63.5% and 35.5%, respectively). The objective of this study is to asses the economic impact of these clinical outcomes in the Spanish setting. METHODS: A retrospective decision-analytical model from the hospital perspective was applied to pooled data from 2 prospective, randomized, controlled-double-blind studies. The model described possible treatment outcomes for patients beginning empiric MRSA-NP treatment. Clinical and other parameters were obtained from published trials and from an expert panel, comprised of 5 Spanish experts experienced in treating NP. Resource use was estimated by the expert panel. Only direct costs (€2007) were considered. The model assumed 50% of suspected MRSA patients had proven MRSA. Model outputs included costs/ patient, cost/death avoided, cost/life-year gained (LYG), and cost/ cure. Sensitivity analyses were carried out to test the robustness of the model. RESULTS: The overall clinical cure rate was 11% greater for linezolid than for vancomycin (71% versus 60%). Average total treatment cost was €16,602 for linezolid versus €15,823 for vancomycin-treated patients; incremental cost €6829. Death rates were 21% (linezolid) versus 34% (vancomycin), with an average 1.9 LYG per linezolid patient in a 65-year-
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COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA SUSPECTED TO BE CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN SPAIN
